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Summary 
 
Intercellular adhesion molecule-1 occurs in a membrane-bound (ICAM-1) and a soluble form 
(sICAM-1). ICAM-1 on vascular endothelial cells mediates leukocyte extravasation during 
inflammatory processes by binding the leukocyte integrins lymphocyte function associated 
antigen-1 (LFA-1) and macrophage antigen-1 (Mac-1). The function of soluble ICAM-1 is 
less well understood. Mouse sICAM-1 was found to induce the secretion of the chemokine 
MIP-2 from mouse astrocytes by a yet unknown mechanism. 
(s)ICAM-1 can be used as a model glycoprotein to see how glycosylation can influence bio-
logical activity, each of its three functions being differently influenced by the glycosylation of 
the protein. Binding to LFA-1 is not affected by the glycosylation of human ICAM-1 whereas 
binding to Mac-1 is hindered by complex-type N-linked glycans. The induction of MIP-2 se-
cretion from mouse astrocytes by mouse sICAM-1 is strongly enhanced by sialylated, galac-
tosylated complex-type N-glycans. 
The present study was aimed at analysing the N-glycan profile of a given glycoprotein and in 
particular of mouse sICAM-1. 
Using the well characterized human α1-acid glycoprotein (AGP) as a reference protein, we 
validated and optimized a technique for the qualitative and quantitative analysis of N-glyco-
sylation patterns. The method encompasses the separation of enzymatically released fluores-
cently labeled N-glycans by anion exchange chromatography according to their charge and 
MALDI TOF mass spectrometry for the identification of glycans contained in peak fractions. 
Using these techniques, the oligosaccharide part of AGP could be characterized correctly, i.e. 
in agreement with data previously reported by several research groups. The methodology also 
showed very good reproducibility as well as robustness over time with regard to retention 
times and relative abundances of glycan species. Despite some drawbacks, including the large 
amount of glycoprotein needed and the rather complex sample preparation procedure, the 
technology was found suitable for its intended purpose. 
Application of the analytical method to sICAM-1 has not yet brought satisfactory results, 
probably due to inadequate sample preparation. Strategies to overcome the problems encoun-
tered and to further optimize the methodology are presented and discussed. 
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Abbreviations 
 
A1 2-AB-labeled monosialylated, galactosylated, biantennary oligosac-
charide standard 
A3 trisialylated, galactosylated, triantennary oligosaccharide standard 
2-AB 2-aminobenzamide 
AGP α1-acid glycoprotein 
BSA bovine serum albumin 
CHO chinese hamster ovary cells 
CV coefficient of variation 
DHB 2, 5-dihydrobenzoic acid 
EDTA ethylene diaminetetraacetate 
ELISA enzyme-linked immunosorbent assay 
Fuc fucose 
Gal galactose 
GalNAc N-acetylgalactosamine 
Glc glucose 
GlcNAc N-acetylglucosamine 
HPLC high performance liquid chromatography 
ICAM-1 intercellular adhesion molecule-1 
IEC ion exchange chromatography 
Ig immunoglobulin 
LFA-1 lymphocyte function associated antigen-1 
Mac-1 macrophage antigen-1 
MALDI TOF MS matrix-assisted laser-desorption/ionization time-of-flight mass 
spectrometry 
Man mannose 
MIP-2 macrophage inflammatory protein-2 
MWCO molecular weight cut-off 
NeuAc N-acetylneuraminic acid 
NeuGc N-glycolylneuraminic acid 
NP-40 Nonidet® P-40 
PIC protease inhibitor cocktail 
PNGase F peptide N-glycosidase F 
Abbreviations  vi 
 
SD standard deviation 
SDS sodium dodecyl sulfate 
SDS PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sICAM-1 soluble intercellular adhesion molecule-1 
TBS Tris buffered saline 
TFA trifluoroacetic acid 
Tris tris(hydroxymethyl)amino methane 
U unit 
 
Three letter codes are used for amino acids. 
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1 Introduction 
 
Aim of the Study 
 
An analytical method to qualitatively and quantitatively analyse the N-glycosylation pattern 
of recombinant proteins was previously established by S. Ali [1]. In the present study this 
established technique was validated and optimized with respect to its suitability to distingiush 
different glycan types and to determine their relative abundances. For this purpose, a model 
glycoprotein with a well-characterized glycosylation pattern, human α1-acid glycoprotein 
(AGP) was used. The final goal was to apply the procedure to mouse soluble intercellular 
adhesion molecule-1 (sICAM-1) expressed in CHO cells, the precise glycosylation pattern of 
which is as yet unknown. We were especially interested in the degree of sialylation, as this 
seems to be of crucial importance to the induction of macrophage inflammatory protein-2 
(MIP-2) secretion from mouse astrocytes by mouse sICAM-1 [2]. 
 
In the following, an introduction to glycosylation in general and to the structure and diversity 
of N-linked glycans is given. Background information on sICAM-1, our glycoprotein of 
interest, as well as on α1-acid glycoprotein, our reference glycoprotein, will be found, fol-
lowed by an overview of the analytical procedure used in the present study. 
 
Glycosylation 
 
Glycosylation is one of the most common forms of posttranslational modification in eu-
karyotic proteins. The majority of the biologically important proteins are glycosylated [3]. 
Glycoproteins are known to be fundamental to many biological processes including fertiliza-
tion, immune defense, viral replication, parasitic infection, cell growth, cell-cell adhesion, 
inflammation and more. Glycoproteins and glycolipids are major components of the outer 
surface of mammalian cells. Oligosaccharide structures change dramatically during develop-
ment and aberrant glycosylation is characteristic for a number of disease states including 
rheumatoid arthritis and cancer metastasis [3]. 
There is no single function for oligosaccharides. The carbohydrate moiety of a glycoprotein 
may participate directly in recognition events [4], but it may also modify the properties of the 
protein [5, 6] by altering its stability, solubility, protease resistance and/or quaternary struc-
ture. These effects arise mainly from the hydrophilicity and the large size of glycan structures 
[7, 8], their size allowing glycans to cover functionally important areas of proteins, to modu-
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late the interactions of glycoconjugates with other molecules and to affect the rate of pro-
cesses which involve conformational changes. 
Increasing evidence shows that there is a close relationship between the structures of glycans, 
particularly at their nonreducing end, and the functions of glycoconjugates. It appears that 
variations of terminal glycosylation, such as fucosylation or sialylation, are crucial and have 
direct implications in biological activities. For full understanding of the specific functions of 
the carbohydrate portions of glycoproteins, a detailed characterization of their structures is 
mandatory [9]. 
The analysis of protein-linked glycans is of increasing importance, both in basic glyco-
biological research and during the production process of glycoprotein pharmaceuticals [10]. 
The use of recombinant proteins as therapeutic agents has dramatically increased over the past 
decade [11]. Among those, there are several examples of therapeutic glycoproteins whose 
biological activity and/or pharmacokinetics depend on glycosylation, which therefore must be 
monitored closely. For example, human recombinant erythropoietin produced in CHO cells 
and being glycosylated shows a more prolonged half-life in blood than a preparation having 
no carbohydrate chains [12]. 
Because the branched, nonlinear nature of glycans and the variety of intersaccharide linkage 
types present additional elements of complexity, the analysis of carbohydrates is much more 
difficult than that of the other two classes of biological polymers, the linear DNA/RNA and 
protein molecules. Furthermore, in contrast to nucleic acids and proteins, there is no universal 
methodology for oligosaccharide analysis [13]. 
 
Diversity and Structure of N-linked Glycans 
 
The two main classes of glycosidic linkages to proteins involve either oxygen in the side 
chain of serine, threonine or hydroxylysine (O-linked glycans) or nitrogen in the side chain of 
asparagine (N-linked glycans). N-glycosylation is much more frequent than O-glycosylation 
and in the present study we exclusively investigated N-linked glycans. To be glycosylated, an 
asparagine residue must form part of the tripeptide Asn-X-Ser/Thr where X can be any amino 
acid apart from proline. However, the presence of this peptide sequence within a protein does 
not guarantee its glycosylation [14]. It has been estimated that between 10 and 30% of poten-
tial glycosylation sites are not occupied [14, 15]. Moreover, site analysis has shown that the 
distibution of different classes of N-linked oligosaccharide structures is frequently specific for 
each N-glycosylation site on a protein. For instance, in α1-acid glycoprotein, Asn15 never car-
ries a tetraantennary glycan, Asn38 never carries glycans with fucose, Asn75 never carries a 
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biantennary glycan and only Asn75 and Asn85 carry tetraantennary glycans with more than one 
fucose [16]. 
Site specific glycosylation of a protein suggests that the 3D structure of the protein plays a 
role in determining the extent and type of its own glycosylation, which has been demonstrated 
in numerous studies of mammalian glycoproteins, e.g. for human erythropoietin, which has 
three glycosylation sites [17]. 
Moreover, the cell type has a major role in determining the extent and type of glycosylation, 
which is both tissue- and species-specific [8]. The inter- and intra-cell line diversity of 
oligosaccharide structures is believed to be related primarily to the presence, concentration, 
kinetic characteristics, and compartmentalization of the individual glycosyltransferases and 
glycosidases found in a given cell [5]. The biosynthesis of N-linked glycans follows a 
complex, enzymatically controlled pathway, involving many different enzyme reactions 
(typically eight for the processing of the Man9GlcNAc2 N-linked oligosaccharide precursor to 
form a complex-type N-glycan) [18, 19]. Each individual enzyme reaction may or may not go 
to completion, giving rise to glycosylated variants or glycoforms of the polypeptide. This also 
explains why the glycosylation pattern of natural glycoproteins may be influenced by 
physiological changes and by some diseases, which may affect one or more enzymes in the 
cell. The glycosylation of recombinant glycoproteins can be sensitive to changes in manufac-
turing conditions (e.g. culture conditions [20]), which therefore must be controlled carefully. 
As their biosynthesis is a well-defined, enzymatically controlled process, only a small subset 
of all theoretical glycan structures is actually synthesized from the rather limited set of build-
ing residues (galactose (Gal), mannose (Man), fucose (Fuc), N-acetylglucosamine (GlcNAc), 
N-acetylneuraminic acid (NeuAc), N-glycolyl neuraminic acid (NeuGc) etc.). 
All N-linked glycans contain the pentasaccharide Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-
4GlcNAc as a common core. On the basis of the structure and the location of glycan residues 
added to the trimannosyl core, N-linked oligosaccharides can be classified into three main 
groups [18, 21]: high-mannose- (oligomannose-), hybrid- and complex-type (Fig. 1). 
High-mannose glycans contain only α-mannose residues attached to the core whereas com-
plex-type glycans contain no mannose residues other than those in the core. Instead they have 
branches (antennae) with N-acetylglucosamine residues attached to the core. The number of 
antennae normally ranges from two to four, but a pentaantennary structure has been reported 
in hen ovomucoid [21]. Complex type N-glycans show the largest structural variations result-
ing mainly from the combination of different numbers of antennae and variations of mono-
saccharides present in the outer chains. 
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The hybrid type N-glycans have the characteristic features of both complex-type and high-
mannose-type glycans. One or two α-mannosyl residues are linked to the Manα1-6 arm of the 
trimannosyl core (as in the case of oligomannose-type glycans) and usually one or two anten-
nae (as found in complex type glycans) are linked to the Manα1-3 arm of the core. 
 
 
 
Fig. 1. Major classes of N-glycans. High-mannose-type (A), hybrid-type (B) and complex-type (C). Symbols: 
White square, GlcNAc; blue circle, Man; green triangle, Fuc; red circle, Gal; black diamond, NeuAc. 
 
A fourth group, actually a subgroup of the complex-type N-glycans, are the poly-N-acetyl-
lactosamine N-glycans containing repeating units Galβ1-4GlcNAcβ1-3- attached to the core. 
Poly-N-acetyllactosamine extensions are most frequently found in tetraantennary glycans. 
The structure of N-glycans is defined by a set of critical features that includes (i) the number 
of antennae, (ii) the degree of sialylation, (iii) the presence of fucosyl residues (on the core 
and/or on the antennae) and (iv) the number of lactosamine units. 
With regard to the physicochemical properties of a glycan, the degree of sialylation is cer-
tainly of major importance. N-acetylneuraminic acid or sialic acid is – as its name indicates – 
an acidic sugar residue which is charged at physiological pH. 
 
Intercellular Adhesion Molecule-1 (ICAM-1) and its Soluble Form (sICAM-1) 
 
We are interested in sICAM-1 because it can be used as a model glycoprotein which is par-
ticularly suitable to study how glycosylation can influence biological activity. 
Intercellular adhesion molecule-1 occurs as both a membrane bound (ICAM-1) and a soluble, 
secreted glycoprotein (sICAM-1, [22]). 
ICAM-1 is a transmembrane glycoprotein which belongs to the group of immunoglobulin (Ig) 
like cell adhesion molecules. It contains five Ig-like domains constituting the extracellular 
 
1 Introduction  5 
 
portion of the molecule [23]. The protein is heavily N-glycosylated and has a molecular 
weight between 85 and 115kDa, depending on the cell type it is expressed in [24-26]. 
Deglycosylation of ICAM-1 results in a protein of 60kDa [26]. 
In vivo, ICAM-1 is expressed by several cell types, including leukocytes and endothelial cells 
[23]. It acts as a binding partner for the leukocyte integrins lymphocyte function associated 
antigen-1 (LFA-1) [25, 27] and macrophage antigen-1 (Mac-1) [28]. Binding of these β2-in-
tegrins by ICAM-1 on the surface of vascular endothelial cells mediates firm adhesion and 
extravasation of leukocytes during inflammatory processes. 
N-linked glycosylation of human ICAM-1 has been reported to reduce its affinity for Mac-1, 
presumably by shielding the ligand binding site. In contrast, glycosylation of human ICAM-1 
seems to have no effect on binding of LFA-1 [29]. 
The soluble, circulating form of ICAM-1, consisting of the extracellular part of ICAM-1, ap-
pears to result from proteolytic cleavage of membrane-bound ICAM-1. Native and recombi-
nant soluble forms of ICAM-1 have been reported to inhibit LFA-1/ICAM-1-mediated adhe-
sion in vitro and it is conceivable that circulating forms of soluble ICAM-1 are regulators of 
LFA-1/ICAM-1 mediated cell-cell interaction in vivo [30]. 
Moreover sICAM-1 has some signaling functions. For instance, mouse sICAM-1 induces the 
secretion of the CXC chemokine macrophage inflammatory protein-2 (MIP-2) from mouse 
astrocytes by an as yet unknown, LFA-1- and Mac-1-independent mechanism [31, 32]. It was 
found that sialylated, galactosylated complex type N-glycans strongly enhance the ability of 
sICAM-1 to induce MIP-2 secretion from primary mouse astrocytes [2]. 
With glycosylation influencing each of the three functions of human/mouse ICAM-1/sICAM-
1 differentially (Fig. 2), it is possible that in vivo ICAM-1 functions are specifically regulated 
by glycosylation. 
From a pharmaceutical standpoint, sICAM-1 may offer the unique possibility to study how 
glycosylation of the same protein may hinder, leave unaffected or enhance biological activity. 
This fact prompted us to seek methods to analyse the glycosylation pattern of this protein and 
to assess its biological activity in various functional assays. The present work focusses on the 
analysis of the glycosylation pattern, especially the degree of sialylation, as sialic acid seems 
to be of crucial importance to MIP-2 induction. 
Murine ICAM-1, in which we are interested in the present study, shows limited homology to 
the human protein sequence (50%) [33], but, like human ICAM-1, consists of five Ig-like do-
mains. It also is a ligand for LFA-1 and Mac-1 in mice [33, 34]. 
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It is known so far that mouse ICAM-1 contains twelve potential N-glycosylation sites [33], 
nine of which are found in the extracellular portion representing sICAM-1. The protein is 
heavily glycosylated with mostly complex-type glycans attached to the N-glycosylation sites. 
Only recently also some evidence of O-glycans was found [2]. 
 
 
 
 
Fig. 2. The three functions of (s)ICAM-1, reported to be differentially influenced by glycosylation. In hu-
mans, binding of LFA-1 (A) is unaffected by the glycosylation of ICAM-1 whereas binding of Mac-1 (B) is 
hindered by complex-type N-glycans [29]. Induction of MIP-2 secretion from mouse astrocytes by mouse 
sICAM-1 is strongly enhanced by sialylated, galactosylated complex-type N-glycans [2]. 
 
α1-Acid Glycoprotein (AGP) 
 
As a reference glycoprotein to establish and validate the procedure for glycan profiling, we 
used human α1-acid glycoprotein, one of the major acute phase proteins in human serum. This 
glycoprotein was first described in 1950 [35, 36] and since then its carbohydrate part has been 
extensively studied by many research groups [16, 37-42]. 
α1-Acid glycoprotein is heavily glycosylated, its molecular weight of around 43kDa including 
45% of carbohydrates [39]. The peptide moiety of the human protein is a single chain of 183 
amino acids to which five highly sialylated, complex-type N-glycans are attached [37, 41]. Its 
carbohydrate part has been thoroughly investigated because it is one of the few serum proteins 
that contains tetra-antennary as well as tri- and biantennary N-linked glycans. 
Because it contains these typical bi-, tri- and tetra-antennary complex-type N-glycans a mix-
ture of glycans derived from human AGP is one of the best libraries of carbohydrates [38]. 
Some of the tri- and tetra-antennary carbohydrate chains are substituted with a fucose residue 
to form the sialyl Lewis X type structure (sLex), NeuAcα2-3Galβ1-4(Fucα1-3)GlcNAc-R. 
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12% of the carbohydrate moiety of α1-acid glycoprotein are sialic acid residues, which can be 
linked in either an α2-3 or α2-6 linkage to galactose. Due to its high degree of sialylation the 
glycoprotein is negatively charged, with a very low pI between 2.7 and 3.2 [43], a property 
which – as well as the type of glycans – it shares with sICAM-1 [2]. 
 
The Analytical Procedure 
 
In the analytical procedure validated and optimized in the present study, N-glycans are enzy-
matically released from the denatured proteins using peptide-N-glycosidase F (PNGase F). 
This enzyme cleaves the Cγ – Nδ bond of the glycosylated asparagine side chain releasing the 
intact N-glycans as glycosylamines, which readily hydrolyse to the glycan. 
As our approach encompasses the release of the N-glycans from the proteins, no information 
concerning the glycosylation site a specific oligosaccharide structure is attached to can be 
derived. 
In two of the AGP samples, sialic acid was removed by digestion with neuraminidase prior to 
the treatment with PNGase F to see how this influences the result of the analysis. 
After removal of protein, salts, and detergents with the help of graphitized carbon packings 
[44] the released oligosaccharide mixtures are reductively aminated with a fluorophore, to 
enable their detection and quantification in the subsequent procedures. We use the fluorescent 
compound 2-aminobenzamide (2-AB) [45]. During the labeling reaction a single molecule of 
2-AB is attached to the reducing terminus of each oligosaccharide, hence the fluorescence of 
the labeled glycans is a direct measure for their molar quantities. 
After the labeling reaction excess 2-AB is removed and the pool glycans are profiled to de-
termine the types of glycans present and their relative molar abundances. The glycans are first 
separated by anion exchange chromatography according to their charge, which depends on the 
number of sialic acid residues attached to the glycan antennae. 
A major advantage of all HPLC systems is that they can be used preparatively. This means 
that the glycans in individual peaks can be collected, the volatile buffers removed, and the 
glycans identified by mass spectrometry. 
In the present study, an additional desalting step is performed prior to mass spectrometric 
analysis of peak fractions although volatile mobile phases are used, in order to minimize am-
biguities in assignments due to different sodium and potassium adducts. 
The collected fractions are analysed by matrix assisted laser desorption/ionization time of 
flight mass spectrometry (MALDI TOF MS) to identify the glycan structures contained in the 
peaks in the chromatogram. MALDI belongs to the mass spectrometric methods which give 
1 Introduction  8 
 
only the parent ion for each glycan and produce spectra which are fairly easy to interpret, al-
though laser energy induced desialylation can sometimes be observed. Like in the ion ex-
change chromatograms, the relative intensities of the peaks in the mass spectra can be used in 
a comparative manner to provide information on the relative abundances of oligosaccharide 
structures. 
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2 Materials and Methods 
2.1 Materials 
Purified water was prepared using a Milli-Q RG water purification system (Millipore, 
Billerica, MA). 
Human α1-acid glycoprotein and protease inhibitor cocktail (PIC) were from Sigma-Aldrich 
Co. (St. Louis, MO). 
Neuraminidase ex. Vibrio cholerae, neuraminidase ex. Arthrobacter ureafaciens and peptide-
N-glycosidase F (PNGase F) were purchased from Roche Diagnostics GmbH (Penzberg, 
Germany). 
The Signal™ 2-AB labeling kit (GKK-404), the GlycoSep™ C HPLC column (I-4721) and 
GlycoClean™ S cartridges (GKI-4726) were obtained from Glyko Inc. (San Leandro, CA). 
Carbograph SPE columns were purchased from Alltech Associates Inc. (Deerfield, IL). 
NuTip™ graphitized carbon 10μl pipette tips were from Glygen Corp. (Columbia, MD). 
Two oligosaccharide standards were used. The trisialylated, galactosylated, triantennary stan-
dard (A3) was purchased unlabeled from Dextra Laboratories Ltd. (Reading, UK) and labeled 
with 2-aminobenzamide using the Signal™ 2-AB labeling kit. The 2-AB-labeled monosialy-
lated, galactosylated, biantennary standard (A1) was obtained from Glyko Inc. (San Leandro, 
CA). 
Acetonitrile HPLC gradient grade was from Scharlau Chemie S.A. (Barcelona, Spain). 
Glacial acetic acid 99% and ammonium hydroxide solution 25% were obtained from Hänseler 
AG (Herisau, Switzerland). 
Trifluoroacetic acid (TFA), 5-methoxysalicylic acid, bovine serum albumin (BSA) and mono-
clonal mouse anti-human α1-acid glycoprotein antibody (A-5566) were purchased from 
Sigma-Aldrich Inc. (St. Louis, MO). 
Peroxidase-labeled goat anti-mouse IgG antibody was from Kirkegaard & Perry Laboratories 
(Gaithersburg, MD). 
HPC4 hybridoma cell line was obtained from ATCC® (Manassas, VA) and HPC4 monoclonal 
antibody was affinity purified using the HPC4 epitope peptide coupled to Affi-Gel 15 
(BioRad Laboratories, Hercules, CA). 
Ultralink® Biosupport Medium was from Pierce Biotechnology (Rockford, IL). 
2,5-Dihydroxybenzoic acid (DHB) puriss p.a. for MALDI MS matrix was from Fluka (Buchs, 
Switzerland). 
All other chemicals were of the highest grade commercially available. 
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2.2 Enzymatic Desialylation of α1-Acid Glycoprotein 
1nmol (~8.3μl) of the native α1-acid glycoprotein in Tris buffered saline (TBS; NaCl 150mM, 
tris(hydroxymethyl)amino methane 20mM, pH 7.4) was desialylated during 60min at 37°C 
using 5mU of recombinant neuraminidase ex. Vibrio cholerae or 10mU of recombinant 
neuraminidase ex. Arthrobacter ureafaciens. 
2.3 Preparation of the Glycan Pools 
0.2-2nmol of glycoprotein were denatured by boiling for 10min in TBS pH 7.4 containing 
0.5% sodium dodecyl sulfate (SDS) and 1% β-mercaptoethanol. 
The glycoproteins were deglycosylated by enzymatic digestion with peptide N-glycosidase F 
(PNGase F) for 16h at 37°C, using 25U of enzyme for 1nmol of α1-acid glycoprotein and 
450U of enzyme for 1nmol of mouse soluble intercellular adhesion molecule-1 (sICAM-1). 
Before the addition of enzyme 1μl of protease inhibitor cocktail (PIC) and Nonidet® P-40 
(NP-40) in 7.5x excess of SDS were added. 
The release of the oligosaccharides was verified by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS PAGE) and Western blot (see 2.11 SDS-PAGE and Western Blot 
Analysis). 
The glycan pool was separated from the protein and other contaminants (salts, detergents, 
reagents) using non-porous graphitized carbon black Carbograph SPE columns (column 
volume 4ml), according to Packer et al. [44]: Columns were conditioned with three column 
volumes of acetonitrile 80% containing 0.1% trifluoroacetic acid (TFA) followed by three 
column volumes of water. Samples were applied to the columns and left for 1 to 2min to al-
low glycans to adsorb to the carbon. Contaminants were washed off with three (for AGP 
samples) to eight (for sICAM-1 samples) column volumes of water, glycans were eluted with 
three column volumes of 25% acetonitrile containing 0.05% TFA. Flow was at all times 
between 0.5 and 1ml per minute (generated by gravity). 
The eluate was frozen at –80°C, lyophilized and stored at –20°C. 
2.4 Preparation of Fluorescently-Labeled Oligosaccharides 
The glycan pool was reductively aminated with 2-aminobenzamide (2-AB) using the Signal™ 
2-AB labeling kit, according to the manufacturer's instructions. Briefly, the dried sample was 
dissolved in 5μl of a solution of 2-AB (0.35M) in dimethyl sulfoxide (DMSO)-glacial acetic 
acid (30% v/v) containing sodium cyanoborohydride (1M). After incubation at 65°C for 3h 
the excess of reagents was removed with a GlycoClean™ S cartridge (post-labeling clean-up), 
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according to the manufacturer's instructions. The oligosaccharide solution was then filtered 
through a IC Millex®-LG Filter Unit (Millipore, Billerica, MA; pore size 0.2μm), frozen at 
–80°C, lyophilized (protected from light) and stored at –20°C in the dark. 
2.5 High Performance Liquid Chromatography (HPLC) 
The dried oligosaccharides were dissolved in 250 to 500μl water. 50μl of this solution, undi-
luted or diluted up to ten-fold, were injected onto the HPLC column. 
HPLC was performed on a Merck Hitachi LaChrom D-7000 system (Merck KgaA, Darm-
stadt, Germany/Hitachi High Technologies America Inc, San Jose, CA) which consisted of a 
HPLC pump (Model No. L-7100), an autosampler (No. L-7200), a fluorescence detector (No. 
L-7480) and an interface (No. D-7000). Merck-Hitachi Model D-7000 Chromatography Data 
Station software version 4.0 was used for data analysis. 
The 2-AB-labeled glycan mixture was separated at room temperature with a GlycoSep™ C 
column (0.4ml/min) using an acetonitrile/water/ammonium acetate gradient [composed of 
water (solvent A), acetonitrile (solvent B) and ammonium acetate 0.5M pH 4.5 (solvent C)], 
modified from Viseux et al. [13]: In a first step the acetonitrile content was decreased from 80 
to 20% while the water proportion was increased accordingly. In a second step, in which 
acetonitrile was kept constant at 20%, the concentration of ammonium acetate (pH 4.5) was 
increased from 0 to 160mM in 35min. The eluate was monitored by fluorescence detection 
(λex 330nm, λem 420nm). 
The ammonium acetate buffer was prepared by diluting acetic acid to 0.5M and adjusting the 
pH to 4.5 with ammonium hydroxide. 
All solvents were filtered and sonicated for approximately 10min at room temperature prior to 
daily chromatographic analyses. 
Peak fractions were collected from samples injected undiluted onto the column, frozen at 
–80°C, lyophilized and stored at –20°C. 
2.6 Sample Cleanup for MALDI TOF MS 
Samples were desalted prior to mass spectrometric analyses using NuTipTM graphitized car-
bon 10μl pipette tips (Glygen Corp., Columbia, MD). Tips were conditioned by pipetting five 
times 10μl of 60% acetonitrile containing 0.05% trifluoroacetic acid (TFA) followed by three 
times 10μl of water. 
Dried HPLC fractions were dissolved in 5μl water. Samples were bound to the carbon by pi-
petting up and down 50 times 2μl volumes (20 times oversampling). Contaminants were 
washed off by pipetting ten times 10μl of water and glycans were eluted with five times 1.5μl 
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of 60% acetonitrile containing 0.05% TFA. Each aliquot was pipetted up and down ten times 
before collection. Samples were vacuum dried. 
2.7 Matrix-assisted Laser-desorption/Ionization Time-of-flight Mass 
Spectrometry (MALDI TOF MS) 
MALDI TOF mass spectra were measured on a 4700 Proteomics Analyzer apparatus (Applied 
Biosystems, Foster City, CA). A nitrogen laser was used to irradiate samples at 337nm, and 
an average of 50 shots was taken. The instrument was operated in linear mode using negative 
polarity, at an accelerating voltage of 20kV. Dried, desalted HPLC fractions were dissolved in 
2μl of methanol 70% and mixed with 2μl of matrix solution, consisting of 0.45% 2,5-dihy-
drobenzoic acid (DHB) and 0.05% 5-methoxysalicylic acid in MeOH 70% containing 10mM 
ammonium citrate (90μl DHB 1% in MeOH 70% were mixed with 10μl 5-methoxysalicylic 
acid 1% in MeOH 70% and 100μl ammonium citrate 20mM in MeOH 70%). 
Samples (1.4μl each) were applied to a polished stainless steel target, and spots were dried at 
room temperature. 
2.8 Affinity Purification of sICAM-1 
Recombinant HPC4 epitope-tagged mouse sICAM-1 was expressed in dihydrofolate reduc-
tase-deficient Chinese hamster ovary (CHO) cells as described in [2]. 
It was purified from the cell supernatants by affinity chromatography, using HPC4 antibody 
coupled to Ultralink® biosupport beads. 2mM CaCl2 and 0.02% (w/v) sodium azide were 
added to the culture medium which was incubated overnight with the HPC4-coupled beads 
(5mg antibody/ml of beads; 1.7μl beads/ml of medium). The next morning the beads were 
collected by centrifugation (10min, 1200 x g) and transferred to a BioRad Econo Column® 
(BioRad Laboratories, Hercules, CA; bed support pore size 20μm). After washing the beads 
with 50 to 60 times their volume TBS low salt (NaCl 100mM, tris(hydroxymethyl)amino 
methane 20mM, pH 7.4) containing 2mM CaCl2 and 0.02% sodium azide, bound protein was 
eluted with TBS low salt, containing 5mM EDTA and 0.02% sodium azide. The protein was 
then dialyzed against three changes of 1lt of TBS (NaCl 150mM, tris(hydroxymethyl)amino 
methane 20mM, pH 7.4) for at least two hours per buffer change. The protein solution was 
sterile filtered through a 0.2μm low protein binding filter membrane (Acrodisc Syringe Filter; 
PALL Gelman Laboratory, Ann Arbor, MI). 
sICAM-1 yields ranged from 0.016 to 0.34mg/lt of culture medium. 
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2.9 Concentration Assessment 
UV absorbance of purified sICAM-1 was measured at 280nm after concentrating the sample 
13-fold using a Centricon® YM-30 concentrator (Amicon Inc., Beverly, MA; MWCO 
=30,000Da). 
For calculation of the concentration the molar absorption coefficient 42200M-1cm-1, calcu-
lated using the formula given in [46] for folded proteins in water, was used. 
The determined concentration was confirmed by comparison to reference sICAM-1 from ear-
lier batches, which was done by Western blot (see 2.11 SDS-PAGE and Western Blot 
Analysis) and ELISA, using the commercial mouse sICAM-1 immunoassay kit (R&D 
Systems Europe, Abingdon, UK; standard curve: 0-20ng/ml; lower detection limit 0.03ng/ml). 
2.10 Biological Activity Assay 
The ability of purified sICAM-1 to induce MIP-2 secretion from primary mouse astrocytes 
was assessed. Mouse astrocytes were isolated from the brains of newborn C57BL/6 mice as 
described in [31] and [47]. 
Preparation of astrocyte cultures, their stimulation with sICAM-1 and quantification of MIP-2 
were done according to [2]. 
Briefly, the evening before stimulation of the astrocytes the culture medium was replaced 
with medium containing 1% fetal bovine serum (FBS). The next morning the cells were 
stimulated with the recombinant mouse sICAM-1 (9 and 37nM). Parallel cell cultures incu-
bated with medium alone were used as controls. After 24h the culture supernatants were col-
lected, centrifuged (2000 x g, 4°C, 10min) and stored at –20°C until analysis by ELISA. The 
commercial mouse MIP-2 immunoassay kit was used (R&D Systems Europe, Abingdon, UK; 
standard curve: 0-500pg/ml; lower detection limit: 1.5pg/ml). 
2.11 SDS-PAGE and Western Blot Analysis 
Proteins were resolved by SDS PAGE (10% polyacrylamide separation gel, 4% stacking gel) 
in a BioRad Mini PROTEAN® 3 cell at 200V during 42min. The prestained broad range 
BioRad SDS-PAGE standard was used as molecular weight marker (BioRad Laboratories, 
Hercules, CA). 
The proteins were transferred to nitrocellulose membranes (BioTraceTM NT, Pall Gelman 
Laboratory, Ann Arbor, MI) using the BioRad TransBlot® SD transfer cell (19V, 20min). 
Blots were blocked with 5% (w/v) non-fat dried milk in either TBS pH 7.4 for sICAM-1 
blots, or in TBS pH 7.4 containing 0.1% w/v Tween-20 for AGP blots, for 90min at room 
2 Materials and Methods  14 
 
temperature or overnight at 4°C and then washed with TBS or TBS/0.1% Tween-20, respec-
tively. To detect sICAM-1, blots were incubated with HPC4 hybridoma cell supernatant for 
one hour at room temperature. After washing four times with TBS containing 2mM CaCl2 
(TBS-CaCl2), the blots were incubated at room temperature for one hour with peroxidase-
labeled secondary antibody (goat anti-mouse IgG), diluted 1:10000 in TBS-CaCl2 containing 
1% bovine serum albumin (BSA). After washing four times with TBS-CaCl2, membranes 
were soaked for 5min in the enhanced chemiluminescence reagent (ECL plus Western 
Blotting Detection System, Amersham Biosciences, UK) and exposed to Kodak BioMax ML 
film (Eastman Kodak Co, Rochester, NY) for a time period of 30s to 7min. 
For detection of AGP, blots were incubated with mouse monoclonal anti-human α1-acid 
glycoprotein antibody, diluted 1:1000 in TBS containing 5% (w/v) non-fat dried milk and 
0.1% w/v Tween-20. The same secondary antibody as for sICAM-1 was used but diluted 
1:10000 in TBS/0.1% Tween-20. AGP blots were washed four times with TBS/0.1% Tween-
20 after each antibody incubation. Detection of immunostained bands was performed as 
described above. 
2.12 Silver Staining 
The degree of purity of the affinity purified sICAM-1 was assessed using silver staining of the 
SDS PAGE resolved proteins. Electrophoresis was performed as described above (2.11 SDS-
PAGE and Western Blot Analysis). The unstained broad range BioRad SDS-PAGE standard 
was used as molecular weight marker (BioRad Laboratories, Hercules, CA). Gel slabs were 
soaked in destaining solution (50% methanol, 10% acetic acid) for 1h, then put in 0.2% 
aqueous periodic acid and left for 1h at 4°C [48] .Thereafter the gel slabs were incubated in 
three changes of 50% ethanol for 20min each. After pretreatment with 1.27mM sodium thio-
sulfate, gel slabs were washed three times for 20sec in ultrapure water. They were then left in 
impregnating solution (11.8mM silver nitrate containing 750μl of formaldehyde solution 35% 
per litre) for 20min. Three more washing steps (20sec each) were performed before the gels 
were placed in developer solution (0.6M sodium carbonate with 500μl formaldehyde 35% and 
20ml pretreatment solution (1.3mM sodium thiosulfate) added per litre) until appropriate 
bands appeared (1 to 5min). After the desired intensity of staining was achieved, the de-
velopment was terminated by replacing the developer solution by destaining solution. 
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3 Results 
3.1 Optimization and Validation of the Analytical Method Using 
Human α1-Acid Glycoprotein (AGP) 
 
An analytical method to qualitatively and quantitatively characterize the glycosylation pattern 
of recombinant proteins was established by Ali [1], using a glycoprotein with a well-
characterized glycosylation pattern, α1-acid glycoprotein (AGP). In the present study we 
reproduced this work and further optimized the technique. In particular, we aimed at iden-
tifying glycan structures by mass spectrometry after their separation by ion exchange chro-
matography (IEC). 
To test the suitability of the analytical method for our actual purpose, the analysis of the gly-
cosylation of mouse sICAM-1, we validated the chromatographic analysis as well as the over-
all procedure including the sample preparation. Intra- and inter-assay precision as well as ro-
bustness of the overall method over time were assessed. Furthermore the detection and quan-
titation limit of the IEC for a single, pure oligosaccharide species, the minimal amount of gly-
coprotein-derived carbohydrate mixture to be injected onto the HPLC column, and the mini-
mal amount of glycoprotein necessary for the analysis were determined. 
Like Ali, we used samples of commercial human α1-acid glycoprotein (AGP) for these pur-
poses. 
 
3.1.1 Separation and Identification of 2-AB-labeled Glycans by Ion Ex-
change Chromatography (IEC) in Combination with MALDI TOF MS 
As previously done by Ali [1], N-glycans enzymatically released from AGP were separated 
by ion exchange chromatography, using an amino-bonded polymer-based stationary phase 
and an acetonitrile/water/ammonium acetate gradient. Our goal was to identify the glycan 
structures contained in the peaks and compare the findings to previously published data about 
the glycosylation of AGP to confirm the accuracy of our analytical method. 
The carbohydrate chains were eluted according to their charges based on the number of sialic 
acid residues present, and differently branched structures (bi-, tri- tetraantennary) were also 
resolved. 
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The elution positions of the different charge states were based on different sialylated standard 
oligosaccharides (mono- and trisialylated, for chromatograms see appendix p. 47) and 
comparison to the chromatogram of AGP glycans given in [13]. 
By comparing the data to those reported by Viseux et al. [13] and Nakano et al. [38], we 
could assign the major peaks in the ion exchange chromatogram (Fig. 3) to differentially 
sialylated glycan classes and confirm the structures by MALDI TOF MS measurement. A list 
of the carbohydrate chains detected, their molecular masses and their abbreviations is given in 
Table 1 and Fig. 5. 
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Fig. 3. Ion exchange chromatographic separation of the 2-aminobenzamide-derivatized N-glycans released 
from human α1-acid glycoprotein. Labeled oligosaccharides were injected onto the GlycoSep C HPLC 
column, which was equilibrated in 80% acetonitrile. The acetonitrile content was linearly decreased to 20% over 
13min and then maintained at this level. At 13min, a linear gradient of ammonium acetate pH 4.5 was initiated, 
going from 0 to 160nM over 35min. S1 to S4 correspond to different charge states, from one to four sialic acids 
(S). Peak labels refer to the major glycan species contained in the peak. All structures found are summarized in 
Table 1 and Fig. 5. Symbols: X includes biantennary (B), triantennary (T), and tetraantennary (Q) N-glycans; S 
sialic acid residue; L lactosamine unit. 
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The earliest eluting peak appearing at ~23min was due to monosialylated species with differ-
ent numbers of antennae (S1). The second group of peaks at around 30min was a mixture of 
disialylated bi-, tri- and tetraantennary carbohydrate chains (S2). The peaks of the third group 
at around 37min corresponded to trisialylated tri- and tetraantennary oligosaccharides (S3) 
and those of the fourth group at around 42min were tetrasialylated tetraantennary species 
(S4). 
Trisialylated triantennary glycans were the major species (contained in the largest peak at 
around 37min). No neutral oligosaccharides were found. Some of the tri- and tetraantennary 
carbohydrate chains were substituted with one or two fucose residues. Small amounts of lac-
tosamine-extended structures were present, accounting for the low-intensity signals in the last 
sialylation cluster (S4). Neither fucosylated nor polylactosamine structures were unequivo-
cally resolved by HPLC but they could easily be identified in the mass spectra. 
These findings agree with previously published data [13, 38, 42] indicating that our method is 
accurate. 
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To illustrate the identification of glycan structures by MALDI TOF MS, the mass spectrum of 
the most heterogenous peak, found at about 29min retention time in the ion exchange chro-
matogram (TS2), is shown in Fig. 4. For the complete set of mass spectra see appendix p. 
48ff. 
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Fig. 4. Mass spectrometric identification of 2-AB-labeled AGP glycans separated by ion exchange 
chromatography. The MALDI TOF MS spectrum obtained for the HPLC peak at a retention time of about 
29min (TS2) is shown, recorded in negative linear mode, as described in Materials and Methods. Peak numbers 
correspond to Table 1 and Fig. 5. 
 
Disialylated tri- and tetraantennary glycans and their fucosylated counterparts were contained 
in the HPLC peak at 29min retention time (TS2). 
The mass spectrum also shows that some desialylation occurred in the procedure following 
the collection of HPLC fractions. Monosialylated structures (1 and 2) were found although the 
peak analysed corresponds to disialylated glycans. 
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Table 1. List of oligosaccharides and their calculated molecular masses (including 2-AB) found in human 
AGP samples. Symbols: B biantennary, T triantennary, Q tetraantennary, F fucosyl residue, S sialic acid resi-
due, L lactosamine unit. Peak labels refer to the peak designations in Fig. 3. All glycans contained in a certain 
peak are listed, including the major ones according to which peaks were labeled. The structures are illustrated in 
Fig. 5. 
 
Structure No. Abbreviation Molecular Mass 
(including 2-AB) 
Peak Label 
    
1 QS 2781.4  
2 TS 2416.1 XS 
3 BS 2050.7  
4 QS2 3072.7 
5 QFS2 3218.8 
6 TS2 2707.3 
7 TFS2 2853.5 
TS2 
8 BS2 2342.0 BS2 
9 QS3 3363.9 
10 QFS3 3510.1 
11 QF2S3 3656.2 
QS3 
12 TS3 2998.6 
13 TFS3 3144.7 
TS3 
14 QLS4 4020.5 
15 QLFS4 4166.7 
16 QL2S4 4385.9 
QLS4 
17 QS4 3655.2 
18 QFS4 3801.3 
19 QF2S4 3847.5 
QS4 
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Fig. 5. Structures of oligosaccharides found in human α1-acid glycoprotein. Numbers refer to Table 1. 
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3.1.2 Precision of the Ion Exchange Chromatographic Analysis and the 
Overall Method Including the Sample Preparation Procedure 
 
We were interested in the repeatability of the chromatographic analysis when the same glycan 
sample was measured several times (intra-assay precision). Moreover, we wanted to know if 
the overall method, including deglycosylation, sample cleanup, derivatization and chroma-
tographic analysis, was reproducible (inter-assay precision), also over a long time period (ro-
bustness over time). 
In addition to the identification of the glycan species, this study aimed at deriving some quan-
titative information on the relative abundance of the different glycans present in the mixture. 
Therefore retention times and relative peak areas of major species which are resolved as cal-
culated by the HPLC software were compared. The peak area values were normalized to the 
most abundant component (the trisialylated, triantennary N-glycan (TS3)), which was set 
equal to 100%. 
 
3.1.2.1 Intra-Assay Precision 
To assess the repeatability of the ion exchange chromatographic analysis with regard to re-
tention times and relative abundances of major glycan species, the same AGP glycan sample 
was measured three times (intra-assay precision; Fig. 6). 
The IEC analysis showed excellent repeatability in retention times, coefficients of variation 
being well below 1%, except for the peak corresponding to monosialylated species (XS) with 
a variability in retention time of 1.23%. 
Relative abundances of the major species resolved were also very well repeatable, variability 
being below 5% for all peaks. 
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Peak Average SD CV 
[%]  [%] 
    
XS 6.6 0.30 4.52 
TS2 44.7 0.61 1.36 
BS2 38.1 0.08 0.20 
QS3 82.2 0.47 0.57 
TS3 100.0 0.00 0.00 
QLS4 17.3 0.28 1.60 
QS4 47.3 1.17 2.47 
Fig. 6. Intra-assay precision with regard to retention times (A) and relative abundances (B) of major spe-
cies. Values indicated represent averages of three analyses of the same sample of 2-AB-labeled glycans from 
AGP. Symbols: X includes biantennary (B), triantennary (T), and tetraantennary (Q) N-glycans; S sialic acid 
residue; L lactosamine unit. SD standard deviation; CV coefficient of variation. 
 
3.1.2.2 Inter-Assay Precision 
The reproducibility of the overall method, comprising release, labeling and IEC analysis of 
the glycans, was monitored by comparing chromatograms obtained for five different, indi-
vidually prepared samples (inter-assay precision; Fig. 7). This series of experiments included 
all steps, namely, the deglycosylation, the sample cleanup, the derivatization and the IEC. 
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Peak Average SD CV 
 [%]  [%] 
XS 5.7 2.82 49.94
TS2 46.6 4.31 9.25 
BS2 38.5 1.20 3.12 
QS3 82.7 1.99 2.41 
TS3 100.0 0.00 0.00 
QLS4 16.9 0.62 3.68 
QS4 47.2 1.04 2.21 
 
Fig. 7. Inter-assay precision with regard to retention times (A) and relative abundances (B) of major spe-
cies. Values indicated represent averages of analyses of five different, individually prepared samples of 2-AB-
labeled glycans from AGP. Symbols: X includes biantennary (B), triantennary (T) and tetraantennary (Q) N-
glycans; S sialic acid residue; L lactosamine unit. SD standard deviation; CV coefficient of variation. 
 
The overall method also showed excellent reproducibility in retention times, coefficients of 
variation being well below 1%, except for the peak corresponding to monosialylated species 
(XS) with a variability in retention time of 1.06%. 
Relative abundances of the major species resolved by HPLC were also well reproducible, 
despite the rather complex sample preparation. Variability was typically below 10% except 
for the smallest peak (XS), where variability was high (50%). 
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3.1.2.3 Robustness over Time 
To assess if the method could be used to monitor batch-to-batch consistency of glycoproteins, 
for instance to compare sICAM-1 samples expressed and purified from cell supernatants at 
different points in time, its robustness over time was tested. 
From the same commercial AGP batch, stored at –20°C, six glycan samples were prepared 
and analysed at three different points in time over a six month period (Table 2). Experiment 1 
was performed by Ali [1] and experiment 2 and 3 three and six months later, respectively. For 
each experiment all preparation steps (PNGase F digestion, 2-AB-labeling, sample cleanup) 
and the IEC analysis were carried out in duplicate. 
The results in Table 2 demonstrate the robustness of the method over time. Again migration 
times showed excellent reproducibility with coefficients of variation below 1% for all peaks. 
Relative abundances of the major species resolved by HPLC were also well reproducible, 
despite the rather complex sample preparation. Coefficients of variation were typically below 
10% except for the smallest peak (XS), where variability was high (22%) and the peak TS2 
with a variability of 10.45%. 
This method can hence be used to monitor the batch-to-batch consistency of glycoproteins. 
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Table 2. Variability of the IEC analyses of the AGP glycan pool over a six-month period with regard to 
retention times (A) and relative abundances (B) of major species. Experiment 2 and 3 were carried out three 
and six months later than experiment 1. Each experiment was performed with two individually prepared AGP 
samples, each analysed once by IEC. Values given for each experiment are the averages of two analyses out of 
one experiment performed in duplicate. Symbols: X includes biantennary (B), triantennary (T) and tetraanten-
nary (Q) N-glycans; S sialic acid residue; L lactosamine unit. SD standard deviation; CV coefficient of varia-
tion. 
A 
              
   experiments      
Glycans 1 2 3 average SD CV [%] 
       
XS 23.37 23.46 23.82 23.6 0.19 0.82 
TS2 29.90 29.65 29.74 29.8 0.10 0.35 
BS2 30.80 30.76 30.82 30.8 0.02 0.08 
QS3 36.06 36.58 36.49 36.4 0.23 0.63 
TS3 36.62 37.17 37.08 37.0 0.24 0.65 
QLS4 41.95 42.69 42.65 42.4 0.34 0.80 
QS4 42.58 43.36 43.32 43.1 0.36 0.83 
              
 
B 
              
   experiments      
Glycans 1 2 3 average SD CV [%] 
       
XS 6.09 4.53 7.84 6.2 1.35 22.00 
TS2 50.86 45.58 58.74 51.7 5.41 10.45 
BS2 38.85 38.26 43.20 40.1 2.20 5.49 
QS3 85.40 82.19 81.12 82.9 1.82 2.20 
TS3 100.00 100.00 100.00 100.0 0.00 0.00 
QLS4 17.07 17.26 16.32 16.9 0.41 2.40 
QS4 47.12 47.77 46.76 47.2 0.42 0.89 
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3.1.3 Detection and Quantitation Limit 
The detection and quantitation limit of the ion exchange chromatography with fluorescence 
detection was determined using known quantities of the 2-AB-labeled monosialylated, bian-
tennary oligosaccharide standard (A1). 
At the same time a calibration curve was generated from which information about the peak 
area corresponding to a certain quantity of glycan could be derived (Fig. 8). 
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Fig. 8. Detection and quantitation limit of the IEC. Increasing amounts of the 2-AB-labeled oligosaccharide 
standard A1 (0.1-5pmol) were injected onto the GlycoSep C HPLC column and eluted with the gradient de-
scribed in Materials and Methods. The fluorescent peak areas measured were plotted against the amount of gly-
can. Both axes are logarithmic. Values given are single measurements. 
 
The fluorescence signal obtained from varying amounts of A1 between 0.1 and 5pmol was 
linear over the range tested. The baseline noise was less than 2% of the height of the peak 
obtained for 0.1pmol of oligosaccharide (not shown). We can therefore say that the detection 
as well as the quantitation limit of the ion exchange chromatography with fluorescence detec-
tion are below 0.1pmol for a single pure glycan species. 
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3.1.4 Minimal Amount of Glycans Necessary for Reliable Determination 
of Relative Abundances by Ion Exchange Chromatography 
As described above, for a single pure glycan species quantitation by IEC was possible down 
to 0.1pmol of glycan. However, we observed that with small quantities of AGP glycans, i.e. 
highly diluted samples, the automatic baseline setting of the HPLC software, on the basis of 
which peak areas were calculated, was inconsistent, although correct chromatograms were 
obtained (superimposition showed no differences, data not shown). 
To determine the minimal amout of glycan mixture to be injected onto the HPLC column for 
reliable quantitation, we analysed a dilution series of one of the AGP samples. The sample 
was injected undiluted (relative concentration 1.0) and diluted 1:2, 1:5, 1:10, 1:20 and 1:40 
(relative concentration 0.5, 0.2, 0.1, 0.05 and 0.025 respectively). 
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Fig. 9. Minimal amount of AGP glycan mixture to be injected onto the HPLC column for reliable 
determination of relative abundances. A dilution series of one of the AGP glycan samples was analysed by 
IEC. Relative abundances of major glycan types, determined on the basis of the peak areas calculated by the 
HPLC software, are shown. Numbers given in the legend correspond to relative concentrations of the sample 
which was applied undiluted (relative concentration 1.0), and diluted 1:2, 1:5, 1:10, 1:20 and 1:40 (relative con-
centrations 0.5, 0.2, 0.1, 0.05 and 0.025 respectively). Values given for 0.025, 0.05, 0.1, 0.2 and 1.0 are single 
measurements, values given for 0.1 and 0.5 are averages of three measurements and standard deviations are 
indicated. Symbols: X includes biantennary (B), triantennary (T) and tetraantennary (Q) N-glycans; S sialic acid 
residue; L lactosamine unit. 
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The relative abundances of major glycan types, determined on the basis of the peak areas cal-
culated by the HPLC software, are shown in Fig. 9 for varying amounts of AGP glycan mix-
tures. 
As can be seen, at a relative concentration of 0.025, i.e. a dilution of the AGP sample of 1:40, 
the HPLC software set baselines so as to give a distorted picture of the relative peak sizes 
compared to more concentrated samples and the smallest peaks (XS and QLS4) were no 
longer detected as such (blue columns missing). 
As estimated using the calibration curve generated with the 2-AB-prelabeled oligosaccharide 
standard A1 (see Fig. 8) in this sample a total amount of glycans of approximately 1.8pmol 
was present. 
At a relative concentration of 0.05 (corresponding to a total amount of glycans of about 
3.6pmol) and a relative concentration of 0.1 (corresponding to a total amount of glycans of 
about 7.5pmol) some abundances, namely peak XS, TS2 and QS3 for 0.05 and peak XS and 
TS2 for 0.1, still differ from the corresponding ones determined for more concentrated 
samples. 
The repeatability (intra-assay precision) of the IEC analysis at the relative glycan concentra-
tion of 0.1 was assessed by correspondingly diluting and measuring one of the AGP samples 
three times. The values given in Fig. 9 for sample 0.1 are averages of these three IEC 
measurements, with standard deviations indicated. Coefficients of variation (not shown in the 
figure) were below 1% for all peaks, except for XS (17.41%), TS2 (16.03%) and BS2 
(1.86%). These results show that the relative abundances determined for small amounts of 
glycans not only differ from the ones determined for samples containing a higher amount of 
glycans, but they also vary considerably. 
Because no differences were visible when chromatograms were superimposed (data not 
shown), these results must be due to the inconsistent automatic baseline setting by the HPLC 
software, on the basis of which peak areas were calculated. 
Taken together, we suggest the maximal dilution of the AGP samples submitted to IEC to be 
1:5, which corresponds to approximately 15pmol of glycans injected onto the column. As can 
be seen in Fig. 9 (samples 0.2, 0.5 and 1.0), with this or higher glycan amounts correct rela-
tive abundances were determined reliably using the present HPLC software. 
The values and standard deviations given in Fig. 9 for the relative concentration 0.5 are the 
same as shown in Fig. 6. In contrast to the ones of sample 0.1, coefficients of variation were 
below 5% for all peaks. 
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3.1.5 Amount of Glycoprotein Necessary for the Analysis 
With respect to our final goal, the analysis of sICAM-1, we wanted to determine the minimal 
starting amount of glycoprotein necessary to obtain correct results in the IEC analysis. 
Therefore, AGP samples with different amounts of glycoprotein were submitted to the sample 
preparation procedure, comprising PNGase F release and 2-AB-labeling of the glycans, and 
analysed by IEC. 
A sufficient amount of glycans, according to the results of the last section (Minimal Amount 
of Glycans Necessary for Reliable Determination of Relative Abundances by Ion Exchange 
Chromatography), was injected onto the HPLC column for all samples. Nevertheless, to com-
pletely dispel ambiguities due to the inconsistent automatic baseline setting by the HPLC 
software, which was discussed above, a superimposition of chromatograms rather than a 
comparison of relative sizes of major peaks is shown (Fig. 10). 
 
0
20
40
60
80
100
20 25 30 35 40 45
Time [min]
R
el
at
iv
e 
ab
un
da
nc
e 
[%
]
2nmol
1nmol
0.5nmol
0.2nmol
 
Fig. 10. Amount of glycoprotein necessary for the analysis. HPLC chromatograms obtained for AGP samples 
differing in the amount of glycoprotein submitted to PNGase F digestion (0.2 to 2nmol) were superimposed. 
Labeled oligosaccharides were injected onto the GlycoSep C HPLC column, which was equilibrated in 80% 
acetonitrile. The acetonitrile content was linearly decreased to 20% over 13min and then maintained at this level. 
At 13min, a linear gradient of ammonium acetate pH 4.5 was initiated, going from 0 to 160nM over 35min. 
 
Correct results could be obtained with as little as 0.2nmol of AGP, as the chromatograms did 
virtually not differ at all, apart from the peak at around 29min, corresponding to tri- and 
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tetraantennary disialylated fucosylated and non-fucosylated species, which interestingly be-
came larger relative to the other peaks the less glycoprotein was used for the analysis. 
 
3.2 Removal of Sialic Acid from Complex-type N-Glycans of Human 
α1-Acid Glycoprotein by Treatment with Neuraminidase 
 
To further test whether the degree of sialylation can be easily monitored by IEC, two samples 
of AGP were treated with neuraminidase prior to deglycosylation by PNGase F. In both cases 
neuraminidase was applied in great excess (5mU or 10mU per nmol of glycoprotein), but di-
gestion was performed at pH 7.4, which is considerably higher than the pH optimum for 
neuraminidase activity (around pH 5) but optimal for subsequent PNGase F treatment. For 
one of the samples neuraminidase ex. Vibrio cholerae (5mU/nmol) was used, the other one 
was treated with the enzyme from Arthrobacter ureafaciens (10mU/nmol). Removal of sialic 
acid was verified by Western blot, where a shift of the protein bands towards lower apparent 
molecular weights could be observed (data not shown). 
The ion exchange chromatograms obtained for the neuraminidase treated AGP samples, in 
comparison to that of an untreated sample, are shown in Fig. 11. 
The charge profile of both samples changed considerably compared to the fully sialylated 
sample, and the sample digested with neuraminidase from Arthrobacter ureafaciens was de-
sialylated more completely than the one treated with the enzyme from Vibrio cholerae. 
Peaks at approximately 23, 30, 37 and 42min retention time correspond to mono-, di-, tri- and 
tetrasialylated species respectively. Neutral glycans elute in the flow through peak (~3min), 
which in these samples was not exclusively due to residual free 2-AB, and in the small bump 
between 10 and 15min, as confirmed by mass spectrometry (Fig. 21, appendix p. 53). 
These data illustrate that the present method is very sensitive in showing changes in sialyla-
tion. 
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Fig. 11. IEC analysis of neuraminidase-treated complex-type N-glycans of human α1-acid glycoprotein. 
IEC chromatograms of the 2-AB-derivatized N-glycans released from human α1-acid glycoprotein pretreated 
with either neuraminidase ex. Vibrio cholerae (A), or neuraminidase ex. Arthrobacter ureafaciens (B) and with-
out desialylation (C). Labeled oligosaccharides were injected onto the GlycoSep C HPLC column, which was 
equilibrated in 80% acetonitrile. The acetonitrile content was linearly decreased to 20% over 13min and then 
maintained at this level. At 13min, a linear gradient of ammonium acetate pH 4.5 was initiated, going from 0 to 
160nM over 35min. 
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3.3 Preparation of Mouse sICAM-1 for Analysis 
 
The final goal of the present study was to apply the optimized and validated procedure to 
mouse soluble intercellular adhesion molecule-1 (sICAM-1) expressed in CHO cells, the pre-
cise glycosylation pattern of which is as yet unknown. 
 
3.3.1 Purity of sICAM-1 Samples 
sICAM-1 to be used for the analysis of its N-glycosylation pattern was affinity purified from 
conditioned media. To assess how pure sICAM-1 was thereafter, we used SDS-PAGE fol-
lowed by silver staining. 
Since the heavily glycosylated proteins are poorly stained by conventional silver staining a 
periodic acid-silver stain for 1,2-diol groups of glycoproteins and polysaccharides in poly-
acrylamide gels [48] was performed. This stain faciliates detection of glycoproteins but still 
stains non-glycosylated proteins more strongly. Hence bands of glycoproteins must not be 
compared quantitatively to bands of non-glycosylated proteins. However, the analysis showed 
that sICAM-1 was quite pure with the main protein contaminant in the sample being bovine 
serum albumin (BSA), probably derived from the CHO cell culture media containing 10% 
fetal calf serum. There were only a few faint bands from other proteins (Fig. 12). 
BSA is not glycosylated and therefore should not influence the analysis of the glycosylation 
pattern of sICAM-1. 
 
Fig. 12. Purity of sICAM-1 samples. 
Silver staining of concentrated solu-
tion of affinity purified sICAM-1, 
performed as described in Materials 
and Methods. sICAM-1 was applied 
undiluted and diluted 1:2, 1:5, 1:10, 
1:20, 1:50 and 1:100 from left to right. 
M marker. Bands at 116kDa corre-
spond to sICAM-1, bands at 66kDa to 
BSA. 
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3.3.2 Concentration Assessment 
After affinity purification sICAM-1 was concentrated 13-fold. To be able to define the 
amount of protein solution needed for the analysis, its concentration was determined. 
Protein concentration was assessed to be 2.1μM by measuring UV absorbance at 280nm. The 
UV spectrum obtained from the concentrated sICAM-1 solution in the wavelenght range of 
230 to 400nm is shown in Fig. 13. 
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Fig. 13. Concentration assess-
ment. UV spectrum of the affinity 
purified concentrated sICAM-1, 
wavelenght ranging from 230 to 
400nm. 
 
 
 
 
 
 
Concentration was also measured by comparison to reference sICAM-1 from earlier batches 
with known concentrations, using Western blot (Fig. 14) and ELISA (Table 3). 
 
 
 
Fig. 14. Comparison of concentrations by Western blot. The first six bands on the left correspond to the indi-
cated amounts of reference sICAM-1. The three bands on the right marked red represent the freshly purified, 
concentrated sICAM-1, diluted 1:100, 1:200 and 1:400. 
 
Western blot showed that the concentration was in a range of approximately 2 to 3μM. 
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The ELISA results are given in [ng/ml]. Since the standard sICAM-1 used for generating the 
ELISA calibration curve has an unknown molecular weight, no conversion from ng/ml into 
nM was possible. 
 
Table 3. Comparison of concentrations by ELISA. Two reference proteins with approximately known con-
centrations were measured in duplicate each and the values given represent averages. The concentrated purified 
sICAM-1 was measured only once. The measured concentrations are given in [ng/ml] rather than [nM] because 
the molecular weight of the standard sICAM-1 contained in the ELISA kit was unknown. 
Protein Approximate known 
Concentration 
[nM] 
Measured 
Concentration 
[ng/ml] 
Reference sICAM-1 I <100 2679 
Reference sICAM-1 II 280 5798 
Concentrated purified sICAM-1 2000 88914 
 
ELISA gave a 15 to 35 times higher concentration for the affinity purified and concentrated 
sICAM-1 than for the two reference proteins measured in parallel. 
Taken together, comparative ELISA and Western blot confirmed that the concentration of the 
purified concentrated sICAM-1 was approximately 2μM as determined by UV spectroscopy, 
although UV absorbance may to a certain extent be due to other proteins in the solution. 
 
3.3.3 Biological Activity Assay 
Next, we tested whether our freshly purified, concentrated sICAM-1 was biologically active 
with regard to induction of MIP-2 secretion from primary mouse astrocytes. 
Two independent experiments were performed in duplicate. Astrocytes were incubated with 9 
and 37nM sICAM-1 for 24h. MIP-2 concentrations in the cell supernatants were then 
measured by ELISA (Fig. 15 and Table 4 (appendix p.54)). 
Our freshly purified sICAM-1 strongly induced MIP-2 production in a dose-dependent man-
ner. 
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Fig. 15. Biological activity assay: Induction of 
MIP-2 secretion from primary mouse astro-
cytes by purified mouse sICAM-1. The cells 
were incubated for 24h with two concentrations 
of sICAM-1 (9 and 37nM) and with medium 
alone as negative control. MIP-2 concentrations 
were strongly elevated when sICAM-1 was pre-
sent during the incubation time. The data are 
presented as average ± SD of four assays (two 
independent experiments, each performed in 
duplicate). 
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3.4 Analysis of the N-Glycosylation Pattern of Mouse sICAM-1 by 
Ion Exchange Chromatography and MALDI TOF MS 
 
The purified, concentrated and biologically active sICAM-1 was submitted to the analytical 
procedure described above, starting with the release of N-glycans by digestion with PNGase 
F. 
 
3.4.1 Release of N-glycans from sICAM-1 by PNGase F Digestion 
The amount of PNGase F necessary for complete deglycosylation strongly depends on the 
glycoprotein. To find out how much PNGase F would be needed to completely deglycosylate 
sICAM-1, we treated sICAM-1 with increasing amounts of enzyme and monitored the re-
moval of N-glycans from the protein by Western blot. 
The minimal amount of enzyme necessary to remove all N-glycans from denatured mouse 
sICAM-1 within 16h at 37°C was found to be around 450U of PNGase F (Roche Diagnostics 
GmbH, Penzberg, Germany) per nmol of glycoprotein (Fig. 16). 
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Fig. 16. Enzymatic release of N-glycans from mouse sICAM-1. The glycoprotein was incubated with different 
amounts of peptide N-glycosidase F (PNGase F) for 16h at 37°C. A) Preliminary estimation of approximate 
amount of enzyme necessary for complete removal of N-glycans from mouse sICAM-1. B) Exact determination 
of enzyme amount according to the range established in A. 
 
3 Results  37 
3.4.2 Ion Exchange Chromatography of sICAM-1 
Using the procedure established for AGP we intended to analyse carbohydrate chains of re-
combinant mouse sICAM-1 expressed in CHO cells. Two samples were individually prepared 
and analysed by IEC. 
For both samples only a single peak was detected at about 3min retention time (Fig. 17). 
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Fig. 17. HPLC chromatogram of the 2-aminobenzamide-derivatized N-glycans released from mouse solu-
ble intercellular adhesion molecule-1. Labeled oligosaccharides were injected onto the GlycoSep C HPLC 
column, which was equilibrated in 80% acetonitrile. The acetonitrile content was linearly decreased to 20% over 
13min and then maintained at this level. At 13min, a linear gradient of ammonium acetate pH 4.5 was initiated, 
going from 0 to 160nM over 35min. 
 
This chromatogram suggests that either no glycans were present or the labeling reaction with 
2-AB failed, thus glycans were not detected although present. 
 
3.4.3 MALDI TOF MS 
To test these possibilities we analysed the collected peak fraction as well as the complete 
sICAM-1 sample by mass spectrometry. No glycans were found (data not shown), suggesting 
that the peak detected in the ion exchange chromatogram is exclusively due to residual free 2-
AB. 
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4 Discussion 
 
In the present work a robust methodology was established for characterizing the N-glycosyla-
tion pattern of proteins, encompassing ion exchange chromatography of released N-glycans 
and MALDI TOF MS measurement of peak fractions. 
We used human α1-acid glycoprotein (AGP) as a reference glycoprotein to validate and opti-
mize the technique. This glycoprotein resembles our protein of interest, mouse soluble inter-
cellular adhesion molecule-1 (sICAM-1), with regard to its glycosylation pattern and its 
acidic pI [2, 43]. It contains five highly sialylated, complex-type N-linked glycans [37, 41]. 
 
Analysis of AGP showed that ion exchange chromatography superbly resolved the fluores-
cently labeled sialic acid-containing oligosaccharides based on the number of sialic acid resi-
dues present. Species with the same degree of sialylation but different numbers of antennae 
were also partly resolved. Assignment of the HPLC elution positions of the different charge 
states and numbers of antennae was based on different sialylated standard oligosaccharides 
and comparison to the chromatogram given in [13]. It should however be noted that no direct 
identification is possible exclusively by IEC. 
MALDI TOF MS measurement of the peak fractions from IEC allowed to identify the struc-
tures of sialo-oligosaccharides. The results of mass spectrometry are in agreement with the 
HPLC analysis but give a much more detailed picture as all species contained in the peaks can 
be identified unambiguously, especially fucosylated and nonfucosylated species as well as 
lactosamine-extended structures which are not clearly resolved by HPLC. 
In agreement with previous reports of several research groups, we found sialylated bi-, tri- 
and tetraantennary oligosaccharides with trisialylated triantennary glycans being the most 
abundant species in human AGP. No neutral oligosaccharides were found. Some of the tri- 
and tetraantennary oligosaccharides contained a fucose residue, most probably to form sialyl 
Lewis x structures. Minor quantities of difucosylated tetraantennary tri- and tetrasialylated 
structures were identified and small amounts of lactosamine-extended tetraantennary glycans 
were present as well. 
 
It should be noted that the combination of IEC and MALDI TOF MS does not allow to de-
termine the positions on the glycans where sialic acid, fucose residues and lactosamine re-
peats are attached. It has been reported that the fucose in human AGP usually occupies a site 
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on one of the GlcNAc residues of the antennae of the larger structures rather than on the first 
GlcNAc of the chitobiose core [37]. 
Furthermore the method does not resolve linkage isomers such as α2-3- and α2-6-linked sialic 
acid. Earlier work using the α2-3-specific sialidase from Newcastle disease virus has shown 
that in human AGP sialic acid is present in both α2-3- and α2-6-linkage [49]. 
 
The fact that the profile determined by ion exchange chromatography very clearly shows the 
degree of sialylation of the glycan pool was corroborated by the analysis of partly desialylated 
samples. Complete desialylation was not achieved even with the very active enzyme from 
Arthrobacter ureafaciens. Complete removal of sialic acid residues not being the principal 
objective of this study, the pH for neuraminidase digestion was not adjusted to the optimum 
of around five in order to maintain ideal conditions for the subsequent PNGase F treatment. 
 
Relative intensities of the peaks in the ion exchange chromatograms as well as in the mass 
spectra can be used in a comparative manner to provide information on the relative abun-
dances of oligosaccharide structures. Here again, mass spectra provide more detailed informa-
tion on all species present whereas HPLC only reveals the relative abundance of major spe-
cies which are resolved. Nevertheless, the HPLC step prior to mass spectrometry is important 
to gather isocharged species because desialylation cannot be completely avoided during the 
MALDI process or the preceding cleanup step, making identification and quantification ex-
clusively by mass spectrometry unreliable with regard to the sialylation profile. 
 
The results summarized in Fig. 6 and Fig. 7 illustrate the excellent reproducibility of the over-
all method up to the chromatography step, despite its complexity. Variability in retention 
times is 1% at most. The elution positions being so exact, the HPLC profile may be inter-
preted directly to predict the structures of the major glycans which elute in a given peak. This 
allows a rapid general overview of total sugar prints. 
Relative abundances were also very reproducible, making the HPLC approach well-suited for 
the quantitation of major glycan species contained in a mixture derived from a glycoprotein. 
Achieving a low variability of results over a long period of time is particularly important if 
the method is used for monitoring batch-to-batch consistency. As shown in Table 2, very 
reproducible results were achieved with six individually prepared AGP samples analysed by 
two independent investigators at three different time points in a six-month period, which 
demonstrates the robustness of the method. 
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Regarding the specificity of the method, errors could possibly occur due to aldehydes other 
than reducing sugar termini labeled by reductive amination with 2-AB. This source of error is 
eliminated by the pre- and post-labeling purification of the glycans as well as the unequivocal 
identification of glycan structures by MALDI TOF MS. 
 
Despite all the advantages, there are some drawbacks of the technique, including in particular 
the rather large amount of glycoprotein (ideally 1nmol) which is needed to achieve reliable 
results (see 3.1.5 Amount of Glycoprotein Necessary for the Analysis) as well as the rela-
tively low sample throughput due to the complex sample preparation procedure. However, the 
suggested 1nmol of starting material is not absolutely mandatory, as variations are in an ac-
ceptable range in chromatograms obtained with only 0.2nmol of glycoprotein. 
Using the standard curve generated with the prelabeled standard glycan (see p. 26, Fig. 8) it 
was estimated that about 60 to 90% of the glycans initially contained in the sample were lost 
during the preparation procedure. Thus starting with 1nmol of AGP, which theoretically con-
tains 5nmol of N-glycans, yields between 500pmol and 2nmol of 2-AB-derivatized glycans 
ready for profiling. 
For the HPLC with fluorescence detection, we determined a detection limit of less than 
0.1pmol of glycan, and it was even reported for a similar system, that the detection limit was 
as low as 10fmol [50]. The simple detection of glycans using the present HPLC technique 
therefore does not constitute a problem. 
However, as outlined under 3.1.4 (Minimal Amount of Glycans Necessary for Reliable 
Determination of Relative Abundances by Ion Exchange Chromatography, p. 27f.), care must 
be taken when interpreting peak areas calculated by the HPLC software as baseline setting is 
often inconsistent, especially when small total amounts of glycans are profiled. 
Therefore, using the present instrumentation and software the amount of glycans injected 
should not be below approximately 15pmol, we even recommend to use 40 to 50pmol, al-
though correct chromatograms can be obtained with less material, as long as there is no need 
for quantitation on the basis of the peak areas calculated by the software. 
Obviously, if peak fractions are to be collected and structures identified by mass spectrome-
try, it is important to sumbit a sufficient total amount of glycans to the ion exchange chroma-
tography. Based on our experience with AGP, we recommend 50 to 100pmol. 
The detection limit for MALDI TOF mass spectrometry was reported to be about 500fmol in 
1998 [51] but great progress in this technique has been made since then. For our MALDI sys-
tem we very roughly estimated the detection limit to be in the low femtomolar range (see ap-
pendix p.55). 
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Despite the limitations mentioned above and the ones concerning linkage information, the 
combined analysis by HPLC and MALDI TOF MS as established by Ali [1] and validated 
and optimized in this study is very valuable as a first step in the analysis of glycoprotein oli-
gosaccharides. 
Additional structural information on linkages, such as Gal(1-3)GlcNAc versus Gal(1-
4)GlcNAc, NeuAc(2-3)Gal versus NeuAc(2-6)Gal, and (2,4)- versus (2,6)-disubstituted man-
nose residues could be derived from methylation analysis [52], tandem mass spectrometry 
experiments (MS/MS) [9, 53, 54] or the combination of exoglycosidase digestions with mass 
spectrometry [55]. 
 
The objective of optimization and validation of our analytical procedure using α1-acid glyco-
protein was to find out whether it was suitable for its intended purpose, namely glycan pro-
filing of sICAM-1. 
A concentrated solution of affinity purified sICAM-1 with the non-glycosylated BSA derived 
from the CHO cell culture media as the main protein contaminant was used for the analysis. 
N-linked glycans could successfully be released from the glycoprotein by PNGase F, although 
a huge amount of enzyme was needed compared to α1-acid glycoprotein. 
As verified by mass spectrometric analyses of the single peak as well as the complete sICAM-
1 samples, all N-linked glycans were lost during the sample preparation procedure. 
Most probably the loss occurred during the extensive washing which was necessary to remove 
the large amounts of buffer salts and, above all, detergents needed for the denaturation of the 
glycoprotein and the subsequent PNGase F digestion. As the concentration of the sICAM-1 
solution was about 60 times lower than the one of the commercial AGP solution, a 60 times 
larger sample volume was taken for sICAM-1 to start with the same amount of glycoprotein. 
Therefore, higher amounts of buffer salts were present and – probably most disturbing – lar-
ger amouts of SDS and NP-40 had to be added for denaturation of the protein and PNGase F 
digestion, respectively, which could hardly be removed. It is also conceivable that these even 
prevented binding of the glycans to the graphitized carbon packing, although no previous re-
ports concerning this problem were found. The mechanism of carbon interaction with carbo-
hydrates is poorly understood and involves both absorption and hydrophobic interaction [44]. 
 
To reduce the large volume of the sample in future experiments, the main objective should be 
to further concentrate the sICAM-1 solution, either with the help of a centrifugal filter device 
(Centricon®) as already done before, by lyophilisation or by protein precipitation. While the 
use of a Centricon® concentrator would result in loss of glycoprotein due to adsorption to the 
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device and lyophilization in concentration of salts and other contaminants, protein precipita-
tion enables concentration of the protein sample as well as purification from undesirable sub-
stances without significant loss of protein. Therefore precedence should be given to the latter 
approach. 
Out of various protein precipitation methods [56] we prefer the one with ice-old acetone, as it 
does not involve any chemicals like for instance trichloroacetic acid (TCA) with uncertain 
effect on the carbohydrate chains and in particular sialic acid content of sICAM-1. A protocol 
can be found in [56] or on http://www.piercenet.com (Technical Resource TR0049.0). 
As a less time-consuming alternative the methanol-chloroform precipitation may be con-
sidered [57]. 
 
To assess the remote possibility of BSA present in the glycoprotein solution interfering with 
the glycan profiling, an AGP sample with BSA added could be submitted to the procedure. If 
interference indeed occurs and results differ from the present ones, BSA must be removed 
from the sICAM-1 solution e.g. by albumin affinity chromatography or size exclusion. How-
ever this should constitute the last possibility as it will most probably be associated with con-
siderable losses of sICAM-1. 
 
Once the sample is successfully prepared, the characterization of the glycosylation pattern of 
mouse sICAM-1 using the present technique possibly requires further optimization con-
cerning the HPLC analysis. In contrast to α1-acid glycoprotein, sICAM-1 might contain small 
amounts of neutral high-mannose-type N-glycans. 
The present amine-bonded HPLC method enables a clear distinction between neutral and 
charged N-linked oligosaccharides. It should be able to separate oligomannosidic type struc-
tures according to size in addition to the separation of sialylated oligosaccharides on the basis 
of charge and size in one chromatographic step. 
An advantage of amine-bonded columns is the ability to perform both as a hydrophilic inter-
action media and as an ion exchange stationary phase [58]. In the initial step of the gradient, 
neutral oligomannosidic structures could be eluted by increasing the polarity of the mobile 
phase using water ("normal phase" conditions). This step could be varied by extending it in 
terms of time (slower decrease of acetonitrile content) as well as in terms of the initial ace-
tonitrile concentration (start with higher acetronitrile content) in order to optimize resolution. 
As soon as the acetonitrile concentration will have been reduced to 20% the linear ammonium 
acetate gradient could be initiated as described, to elute mono-, di-, tri- and tetrasialylated 
species according to their charge. 
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The ability to resolve neutral and acidic glycans simultaneously is particularly useful where 
acidic sugars are likely to play a functional role as in the case of the MIP-2 induction from 
mouse astrocytes by mouse sICAM-1. 
 
In future studies, the technology could be applied to compare the glycosylation of sICAM-1 
expressed in CHO cells to the glycosylation of sICAM-1 synthesized in different mouse tis-
sues under different pathophysiological conditions. As glycosylation depends on the cell type 
expressing a glycoprotein as well as on the disease state the signaling function of sICAM-1 
might be favoured in specific cell types and/or under certain pathophysiological conditions 
[2]. 
To derive more structural information, the present technique could even be combined with 
exoglycosidase digestions as described in [50]. For example, sialic acid linkage could be 
determined using the α2-3-linkage-specific sialidase from Newcastle disease virus. This might 
be interesting for sICAM-1 expressed in cell types other than CHO cells. The latter synthesize 
sialylated glycans with sialic acid occuring in α2-3-linkage only [59]. 
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Fig. 18. HPLC chromatogram of the 2-AB-derivatized trisialylated triantennary oligosaccharide standard 
A3. As verified by mass spectrometry, the smaller peaks at retention times around 30min and around 23min 
correspond to di- and monosialylated species, resulting from partial desialylation of A3 (retention time approxi-
mately 37min). 
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Fig. 19. HPLC chromatogram of the 2-AB-prelabeled monosialylated biantennary oligosaccharide stan-
dard A1. 
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Fig. 20. MALDI TOF mass spectra of HPLC peak fractions of sialylated AGP glycans. Spectra were re-
corded in negative linear mode, as described in Materials and Methods. A) IEC retention time 2-4.5min, no gly-
cans were detected, indicating residual free 2-AB to be responsible for this peak; B) retention time 22-25min, bi- 
tri- and tetraantennary monosialylated species were detected; C) retention time 28-30.5min, tri- and tetraanten-
nary disialylated glycans and their corresponding fucosylated structures were detected; D) retention time 30.5-
33.5min, biantennary disialylated glycans were detected; E) retention time 33.5-36.5, minor quantities of 
tetraantennary trisialylated mono- and difucosylated structures were detected; F) retention time 36.5-39, tetraan-
tennary trisialylated structures along with triantennary trisialylated fucosylated and non-fucosylated strucutures 
were detected; G) retention time 39.5-42.5, minor quantities of polylactosamine-extended, tetraantennary tetra-
sialylated fucosylated and non-fucosylated glycans were detected; H) retention time 42.5-45min, tetraantennary 
tetrasialylated mono- and difucosylated and non-fucosylated glycans were detected. Some desialylation occurred 
in the procedure following the collection of HPLC fractions, therefore in most spectra less sialylated structures 
than correspond to the collected peak are found in addition to the ones mentioned. I) Mass spectrum of AGP 
glycans without prior separation by ion exchange chromatography. 
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Fig. 21. MALDI TOF mass spectra of desialylated AGP glycans eluted in the HPLC peak at retention time 
~3min. Spectra were recorded in negative linear mode, as described in Materials and Methods. Mass spectra of 
collected peak fractions (retention time ~3min) from samples digested with neuraminidase ex. Vibrio cholerae 
(A), or neuraminidase ex. Arthrobacter ureafaciens. For the corresponding chromatograms see Fig. 11 (p. 31). 
For a mass spectrum of the flow through peak of a sample without neuraminidase treatment see Fig. 20 A. 
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Table 4. Activity assay. MIP-2 concentrations measured by ELISA in supernatants of primary mouse astrocytes 
incubated with 0, 9 and 37nM sICAM-1 for 24h. Two independent experiments were performed in duplicate 
each. SD standard deviation; CV coefficient of variation. 
 
                 
 1st experiment 2nd experiment     
sICAM-1 MIP-2 MIP-2 MIP-2 MIP-2  Average SD CV 
[nM] [pg/ml] [pg/ml] [pg/ml] [pg/ml]  [pg/ml]   [%] 
         
0 8.8 3.0 10.8 5.8  7 3.0 41.7 
9 919.4 697.5 801.4 921.5  835 93.1 11.1 
37 4227.9 3923.7 3017.8 3455.0  3656 460.0 12.6 
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Fig. 22. MALDI TOF mass spectrum of the biantennary, monosialylated oligosaccharide standard A1. The 
spectrum was recorded in negative linear mode, as described in Materials and Methods. 5pmol of the standard 
were spotted on the MALDI target. 
5pmol of the oligosaccharide standard A1 resulted in a signal of 13000. By comparing this to 
spectra with signals hardly above baseline noise (e.g. Fig. 20 E, signal height ~50) the detec-
tion limit for MALDI TOF MS was very roughly estimated to be around 0.02pmol. 
 
